Biomarkers & Diagnosis
- Milestone 9.A •
Develop and validate translatable biomarkers for their use in preclinical and clinical drug development...
- Milestone 9.B •
Accelerate the development of the next generation CNS imaging ligands and biofluid molecular signatures...
- Milestone 9.C •
Initiate development of imaging and/or fluid biomarkers to demonstrate target engagement for 5 novel therapeutic targets for AD...
- Milestone 9.D •
Incorporate imaging and/or fluid biomarkers into Phase II (proof of concept) drug trials to provide proof of mechanism and/or evidence of target engagement as trials...
- Milestone 9.E •
Incorporate imaging and/or fluid biomarkers into Phase III (pivotal) drug trials to select subjects and/or provide evidence of target engagement...
- Milestone 9.F •
Initiate studies to develop minimally invasive biomarkers for detection of cerebral amyloidosis, AD and AD-related dementias pathophysiology.
- Milestone 9.G •
Initiate studies to link peripheral blood-based molecular signatures and central imaging and CSF biomarkers.
- Milestone 9.H •
Launch research programs to develop and validate sensitive neuropsychological and behavioral assessment measures...
- Milestone 9.I •
Develop and test methods for the standardization of immunoassays and mass-spectrometry/single reaction monitoring assay...
Enabling Technologies and Disease Monitoring
- Milestone 11.A •
Develop research programs aimed at evaluating a variety of technologies for in-place monitoring of individuals at all stages of disease...
- Milestone 11.B •
Continue to develop standard outcome measures to enable data comparisons across studies...
- Milestone 11.C •
Embed wearable technologies as well as pervasive computing approaches in existing and new clinical research...
- Milestone 11.D •
Support the development and commericialization of wearables that can increase rigor in measuring environmental exposures and intervention dosing...
- Milestone 11.E •
Build end-to-end secure, high frequency data capture platforms to enable continuous monitoring of research participants...
- Milestone 11.F •
Maintain an open-access national repository of evidence -based tools for cognitive assessment...
- Milestone 11.G •
Launch programs on impact of diagnosis on individuals and families, to include individual response and social impacts.
AD Related Dementias - Specific
- Milestone 9.J •
Longitudinal antemortem LBD characterization
- Milestone 9.K •
Detect cognitive impairment when a patient or relative voices a concern to health care providers.
- Milestone 9.L •
Improving differential diagnosis of symptomatic cognitive impairment.
- Milestone 9.M •
Develop diagnostics/biomarkers in asymptomatic individuals.
- Milestone 9.N •
Determining the value of screening for clinically relevant cognitive impairment in the absence of a cognitive complaint.
- Milestone 9.O •
Neuroimaging characterization of LBD
- Milestone 9.P •
LBD biomarker development
- Milestone 9.Q •
Develop FTD biomarkers for diagnosis and disease progression.
- Milestone 9.R •
Develop and validate longitudinally tracked noninvasive markers of key vascular processes related to cognitive and neurologic impairment.
- Milestone 9.S •
Develop novel blood/CSF biomarkers or PET ligands for FTLD-tau, -TDP or -FUS during life
- Milestone 9.T •
Biomarker and risk profiles for TDP-43
- Milestone 11.H •
Improve tools for assessment of risks, preclinical characteristics, and costs among health disparities populations by leveraging existing data/cohorts, designing targeted studies, and using
- Milestone 11.I •
Increase utilization of culturally- and linguistically-appropriate assessment tools within ongoing and newly generated studies of AD/ADRD and vascular health intervention trials.
- Milestone 11.J •
Increase training of health professionals to meet the demand for cognitive impairment and dementia diagnosis, care, and need for human-based research.
- Milestone 11.K •
Intervention studies to mitigate reversible causes of cognitive dysfunction in at-risk individuals
- Milestone 11.L •
Characterize the clinical phenotype of progressive dementia associated with TBI
- Milestone 11.M •
Intervention studies to investigate reversible causes of dementia.